Which has preferable earnings & valuation, TFX or NVCR?

NovoCure has lower revenue, but higher earnings than Teleflex. NovoCure is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Teleflex $1.99B 2.97 -$905.64M -$23.29 N/A NovoCure $699.19M 2.97 -$136.23M -$1.30 N/A

Is TFX or NVCR more profitable?

NovoCure has a net margin of -21.25% compared to Teleflex's net margin of -39.67%. Teleflex's return on equity of 11.93% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets Teleflex -39.67% 11.93% 5.44% NovoCure -21.25% -44.00% -15.85%

Does the media refer more to TFX or NVCR?

In the previous week, Teleflex had 7 more articles in the media than NovoCure. MarketBeat recorded 12 mentions for Teleflex and 5 mentions for NovoCure. Teleflex's average media sentiment score of 0.93 beat NovoCure's score of 0.48 indicating that Teleflex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teleflex 8 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive NovoCure 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to NVCR or MMED?

In the previous week, MiniMed Group had 5 more articles in the media than NovoCure. MarketBeat recorded 10 mentions for MiniMed Group and 5 mentions for NovoCure. MiniMed Group's average media sentiment score of 1.00 beat NovoCure's score of 0.48 indicating that MiniMed Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NovoCure 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral MiniMed Group 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, HAE or NVCR?

Haemonetics has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Haemonetics $1.33B 3.54 $97.31M $2.04 50.90 NovoCure $699.19M 2.97 -$136.23M -$1.30 N/A

Is HAE or NVCR more profitable?

Haemonetics has a net margin of 7.12% compared to NovoCure's net margin of -21.25%. Haemonetics' return on equity of 27.55% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets Haemonetics 7.12% 27.55% 9.65% NovoCure -21.25% -44.00% -15.85%

Does the media favor HAE or NVCR?

In the previous week, Haemonetics had 15 more articles in the media than NovoCure. MarketBeat recorded 20 mentions for Haemonetics and 5 mentions for NovoCure. Haemonetics' average media sentiment score of 0.67 beat NovoCure's score of 0.48 indicating that Haemonetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Haemonetics 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NovoCure 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, LIVN or NVCR?

NovoCure has lower revenue, but higher earnings than LivaNova. NovoCure is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LivaNova $1.47B 3.01 -$242.47M $3.38 23.76 NovoCure $699.19M 2.97 -$136.23M -$1.30 N/A

Is LIVN or NVCR more profitable?

LivaNova has a net margin of 12.82% compared to NovoCure's net margin of -21.25%. LivaNova's return on equity of 16.35% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets LivaNova 12.82% 16.35% 7.76% NovoCure -21.25% -44.00% -15.85%

Does the media refer more to LIVN or NVCR?

In the previous week, NovoCure had 2 more articles in the media than LivaNova. MarketBeat recorded 5 mentions for NovoCure and 3 mentions for LivaNova. LivaNova's average media sentiment score of 1.08 beat NovoCure's score of 0.48 indicating that LivaNova is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NovoCure 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, NVCR or ITGR?

Integer has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NovoCure $699.19M 2.97 -$136.23M -$1.30 N/A Integer $1.85B 2.30 $102.81M $3.66 34.23

Is NVCR or ITGR more profitable?

Integer has a net margin of 6.97% compared to NovoCure's net margin of -21.25%. Integer's return on equity of 12.79% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets NovoCure -21.25% -44.00% -15.85% Integer 6.97% 12.79% 6.48%

Does the media prefer NVCR or ITGR?

In the previous week, Integer had 18 more articles in the media than NovoCure. MarketBeat recorded 23 mentions for Integer and 5 mentions for NovoCure. Integer's average media sentiment score of 0.57 beat NovoCure's score of 0.48 indicating that Integer is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NovoCure 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Integer 10 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

NovoCure (NVCR) Competitors

$17.82 -0.17 (-0.94%)

As of 08/28/2026 04:00 PM Eastern

Compare

NVCR vs. TFX, MMED, HAE, LIVN, and ITGR

Should you buy NovoCure stock or one of its competitors? NovoCure's main competitors and comparable companies include Teleflex (TFX), MiniMed Group (MMED), Haemonetics (HAE), LivaNova (LIVN), and Integer (ITGR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does NovoCure compare to Teleflex?

Teleflex (NYSE:TFX) and NovoCure (NASDAQ:NVCR) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

Teleflex has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market. Comparatively, NovoCure has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market.

NovoCure has a net margin of -21.25% compared to Teleflex's net margin of -39.67%. Teleflex's return on equity of 11.93% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teleflex	-39.67%	11.93%	5.44%
NovoCure	-21.25%	-44.00%	-15.85%

NovoCure has lower revenue, but higher earnings than Teleflex. NovoCure is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teleflex	$1.99B	2.97	-$905.64M	-$23.29	N/A
NovoCure	$699.19M	2.97	-$136.23M	-$1.30	N/A

Teleflex currently has a consensus price target of $152.90, indicating a potential upside of 9.36%. NovoCure has a consensus price target of $21.20, indicating a potential upside of 18.97%. Given NovoCure's higher possible upside, analysts plainly believe NovoCure is more favorable than Teleflex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teleflex	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42
NovoCure	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

95.6% of Teleflex shares are owned by institutional investors. Comparatively, 84.6% of NovoCure shares are owned by institutional investors. 0.7% of Teleflex shares are owned by company insiders. Comparatively, 6.6% of NovoCure shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Teleflex had 7 more articles in the media than NovoCure. MarketBeat recorded 12 mentions for Teleflex and 5 mentions for NovoCure. Teleflex's average media sentiment score of 0.93 beat NovoCure's score of 0.48 indicating that Teleflex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teleflex	8 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
NovoCure	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Teleflex beats NovoCure on 11 of the 17 factors compared between the two stocks.

How does NovoCure compare to MiniMed Group?

NovoCure (NASDAQ:NVCR) and MiniMed Group (NASDAQ:MMED) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk.

84.6% of NovoCure shares are held by institutional investors. 6.6% of NovoCure shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

NovoCure has higher earnings, but lower revenue than MiniMed Group. MiniMed Group is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$699.19M	2.97	-$136.23M	-$1.30	N/A
MiniMed Group	$3.10B	1.82	-$333M	-$0.68	N/A

MiniMed Group has a net margin of 0.00% compared to NovoCure's net margin of -21.25%. MiniMed Group's return on equity of 0.00% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-21.25%	-44.00%	-15.85%
MiniMed Group	N/A	N/A	N/A

NovoCure presently has a consensus target price of $21.20, suggesting a potential upside of 18.97%. MiniMed Group has a consensus target price of $21.62, suggesting a potential upside of 7.54%. Given NovoCure's higher possible upside, equities research analysts plainly believe NovoCure is more favorable than MiniMed Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
MiniMed Group	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, MiniMed Group had 5 more articles in the media than NovoCure. MarketBeat recorded 10 mentions for MiniMed Group and 5 mentions for NovoCure. MiniMed Group's average media sentiment score of 1.00 beat NovoCure's score of 0.48 indicating that MiniMed Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NovoCure	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
MiniMed Group	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

MiniMed Group beats NovoCure on 9 of the 15 factors compared between the two stocks.

How does NovoCure compare to Haemonetics?

Haemonetics (NYSE:HAE) and NovoCure (NASDAQ:NVCR) are both mid-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

99.7% of Haemonetics shares are held by institutional investors. Comparatively, 84.6% of NovoCure shares are held by institutional investors. 2.1% of Haemonetics shares are held by company insiders. Comparatively, 6.6% of NovoCure shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Haemonetics has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market. Comparatively, NovoCure has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

Haemonetics has a net margin of 7.12% compared to NovoCure's net margin of -21.25%. Haemonetics' return on equity of 27.55% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Haemonetics	7.12%	27.55%	9.65%
NovoCure	-21.25%	-44.00%	-15.85%

Haemonetics has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Haemonetics	$1.33B	3.54	$97.31M	$2.04	50.90
NovoCure	$699.19M	2.97	-$136.23M	-$1.30	N/A

Haemonetics presently has a consensus target price of $97.56, suggesting a potential downside of 6.04%. NovoCure has a consensus target price of $21.20, suggesting a potential upside of 18.97%. Given NovoCure's higher possible upside, analysts clearly believe NovoCure is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Haemonetics	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73
NovoCure	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

In the previous week, Haemonetics had 15 more articles in the media than NovoCure. MarketBeat recorded 20 mentions for Haemonetics and 5 mentions for NovoCure. Haemonetics' average media sentiment score of 0.67 beat NovoCure's score of 0.48 indicating that Haemonetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Haemonetics	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NovoCure	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Haemonetics beats NovoCure on 14 of the 17 factors compared between the two stocks.

How does NovoCure compare to LivaNova?

LivaNova (NASDAQ:LIVN) and NovoCure (NASDAQ:NVCR) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

LivaNova currently has a consensus target price of $83.50, suggesting a potential upside of 3.96%. NovoCure has a consensus target price of $21.20, suggesting a potential upside of 18.97%. Given NovoCure's higher possible upside, analysts clearly believe NovoCure is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.55
NovoCure	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

LivaNova has a net margin of 12.82% compared to NovoCure's net margin of -21.25%. LivaNova's return on equity of 16.35% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	12.82%	16.35%	7.76%
NovoCure	-21.25%	-44.00%	-15.85%

LivaNova has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, NovoCure has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

NovoCure has lower revenue, but higher earnings than LivaNova. NovoCure is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.47B	3.01	-$242.47M	$3.38	23.76
NovoCure	$699.19M	2.97	-$136.23M	-$1.30	N/A

In the previous week, NovoCure had 2 more articles in the media than LivaNova. MarketBeat recorded 5 mentions for NovoCure and 3 mentions for LivaNova. LivaNova's average media sentiment score of 1.08 beat NovoCure's score of 0.48 indicating that LivaNova is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NovoCure	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

97.6% of LivaNova shares are owned by institutional investors. Comparatively, 84.6% of NovoCure shares are owned by institutional investors. 0.4% of LivaNova shares are owned by insiders. Comparatively, 6.6% of NovoCure shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

LivaNova beats NovoCure on 11 of the 16 factors compared between the two stocks.

How does NovoCure compare to Integer?

NovoCure (NASDAQ:NVCR) and Integer (NYSE:ITGR) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, media sentiment, institutional ownership, profitability and dividends.

NovoCure has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market. Comparatively, Integer has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market.

NovoCure presently has a consensus price target of $21.20, suggesting a potential upside of 18.97%. Integer has a consensus price target of $109.86, suggesting a potential downside of 12.32%. Given NovoCure's stronger consensus rating and higher possible upside, equities analysts clearly believe NovoCure is more favorable than Integer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Integer	0 Sell rating(s)	13 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.07

Integer has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$699.19M	2.97	-$136.23M	-$1.30	N/A
Integer	$1.85B	2.30	$102.81M	$3.66	34.23

Integer has a net margin of 6.97% compared to NovoCure's net margin of -21.25%. Integer's return on equity of 12.79% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-21.25%	-44.00%	-15.85%
Integer	6.97%	12.79%	6.48%

84.6% of NovoCure shares are held by institutional investors. Comparatively, 99.3% of Integer shares are held by institutional investors. 6.6% of NovoCure shares are held by company insiders. Comparatively, 1.1% of Integer shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Integer had 18 more articles in the media than NovoCure. MarketBeat recorded 23 mentions for Integer and 5 mentions for NovoCure. Integer's average media sentiment score of 0.57 beat NovoCure's score of 0.48 indicating that Integer is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NovoCure	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Integer	10 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Integer beats NovoCure on 10 of the 16 factors compared between the two stocks.

Get NovoCure News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NVCR vs. The Competition

Export

Metric	NovoCure	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.08B	$5.84B	$7.20B	$12.90B
Dividend Yield	N/A	1.75%	2.54%	11.28%
P/E Ratio	-13.71	25.92	273.16	25.45
Price / Sales	2.97	68.06	592.32	71.88
Price / Cash	N/A	33.03	76.74	53.00
Price / Book	6.14	6.18	12.98	6.14
Net Income	-$136.23M	$149.01M	$3.48B	$348.86M
7 Day Performance	4.21%	-0.24%	0.13%	-0.80%
1 Month Performance	17.01%	6.18%	7.08%	4.13%
1 Year Performance	44.53%	6.30%	24.67%	15.17%

NovoCure Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NVCR NovoCure	2.5785 of 5 stars	$17.82 -0.9%	$21.20 +19.0%	+44.5%	$2.08B	$699.19M	N/A	1,605	News Coverage Positive News Analyst Downgrade
TFX Teleflex	3.4936 of 5 stars	$138.31 -0.4%	$151.80 +9.8%	+10.5%	$5.88B	$1.99B	N/A	15,500	Analyst Forecast Short Interest Increase
MMED MiniMed Group	2.1311 of 5 stars	$19.94 -2.5%	$21.62 +8.4%	N/A	$5.74B	$3.10B	N/A	2,800	News Coverage Lockup Expiration
HAE Haemonetics	2.6675 of 5 stars	$108.34 -0.4%	$97.56 -10.0%	+90.1%	$4.95B	$1.35B	53.11	3,009	Analyst Revision
LIVN LivaNova	2.4029 of 5 stars	$78.26 -0.6%	$83.50 +6.7%	+42.5%	$4.34B	$1.39B	23.15	3,300

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NVCR) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NovoCure (NVCR) Competitors